Cambridge-based Jounce Therapeutics, Inc. is making waves in the clinical-stage immunotherapy arena, as their cutting edge research targets the development of groundbreaking therapies to combat cancer. Their current focus lies on vopratelimab, a monoclonal antibody that is currently undergoing Phase II clinical trials. This clinical-stage drug is designed to bind to Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which could provide a breakthrough in cancer treatment. But that's not all - the company is also in the process of developing JTX-8064, a monoclonal antibody that targets leukocyte immunoglobulin like receptor B2, a cell surface receptor expressed on macrophages, as well as Pimivalimab, an anti-PD-1 antibody for combination therapy. Looking to the future, Jounce also has a range of promising preclinical products in their pipeline, including JTX-1484, a drug designed to reduce myeloid-mediated immune suppression, and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression while also activating T and NK cells. Founded in 2012, Jounce Therapeutics Inc. is quickly emerging as a major contender in the field of immunotherapy, with their groundbreaking work potentially changing the face of cancer treatment forever.